PARP inhibitors have been shown to induce the expression of PDL-1 and to enhance the antitumor effects of anti-PD-1 antibodies in mouse models of breast and ovarian cancer; only a small cohort of patients have been studied with this combination; thus, this requires further investigation [77]. Here, PARP1 is linked to ovarian cancer.